(Q34478828)

2 August 2017

1 reference

title

Aggressive multiple sclerosis: proposed definition and treatment algorithm (English)

1 reference

2 August 2017

0 references

Carolina A Rush

1

1 reference

2 August 2017

Heather J MacLean

series ordinal

2

1 reference

2 August 2017

Mark S Freedman

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

2 June 2015

1 reference

2 August 2017

published in

Nature Reviews Neurology

1 reference

2 August 2017

volume

11

1 reference

2 August 2017

issue

7

1 reference

2 August 2017

page(s)

379-389

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2015.85

2 August 2017

exact match

0 references

cites work

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Prognostic factors for multiple sclerosis: the importance of natural history studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Defining the clinical course of multiple sclerosis: the 2013 revisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Demographic and clinical characteristics of malignant multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Characterising aggressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Alemtuzumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Induction vs. escalating therapy in multiple sclerosis: practical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Concepts of induction and escalation therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Induction therapy for patients with multiple sclerosis: why? When? How?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The clinical pharmacokinetics of cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

High-dose cyclophosphamide in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Treatment of multiple sclerosis with anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Disability progression in multiple sclerosis is slower than previously reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Predictors of relapse rate in MS clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cognitive presentation of multiple sclerosis: evidence for a cortical variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Neuropathology of multiple sclerosis-new concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Severe cystitis induced by cyclophosphamide. Role of surgical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Multiple sclerosis: long-term remission after a high dose of cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Mitoxantrone for multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Multiple Sclerosis: Disability and Mortality in a Cohort of Clinically Diagnosed Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.85

Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease

31 March 2020

1 reference

12 December 2020

Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis

1 reference

12 December 2020

Multiple sclerosis: early prognostic guidelines

1 reference

12 December 2020

Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide

1 reference

12 December 2020

Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms

1 reference

12 December 2020

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

1 reference

12 December 2020

Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis

1 reference

12 December 2020

Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis?

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2015.85

1 reference

Dimensions Publication ID

2 August 2017

1039299930

0 references

Fatcat ID

release_gohqy7m7gvgl5oro5zsujgndve

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gohqy7m7gvgl5oro5zsujgndve

24 November 2022

mapped directly with Wikidata item

1 reference